By Scientia Professor Gregory John Dore

Journal articles

Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C, 2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2020.102693

Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010

Dore GJ; Martinello M; Alavi M; Grebely J, 2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x

Marshall AD; Grebely J; Dore GJ; Treloar C, 2020, 'Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience', Drug and Alcohol Dependence, 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107705

Boettiger DC; Salazar-Vizcaya L; Dore GJ; Gray RT; Law MG; Callander D; Lea T; Rauch A; Matthews GV, 2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, 70, pp. 106 - 113, http://dx.doi.org/10.1093/cid/ciz164

Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562

Geddes L; Iversen J; Wand H; Esmaeili A; Tsui J; Hellard M; Dore G; Grebely J; Dietze P; Bruneau J; Prins M; Morris MD; Shoukry NH; Lloyd AR; Kim AY; Lauer G; Cox AL; Page K; Maher L; Lloyd A; Dore G; Dietze P, 2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, 70, pp. 123 - 131, http://dx.doi.org/10.1093/cid/ciz162

He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ, 2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, 51, pp. 34 - 52, http://dx.doi.org/10.1111/apt.15598

Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Durán R; Fischer J; Nattermann J; D’Ambrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2

Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196

Alavi M; Law MG; Dore GJ, 2019, 'Reply to: “Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis”', Journal of Hepatology, 71, pp. 1254 - 1255, http://dx.doi.org/10.1016/j.jhep.2019.07.011

Safreed-Harmon K; Blach S; Aleman S; Bollerup S; Cooke G; Dalgard O; Dillon JF; Dore GJ; Duberg AS; Grebely J; Boe Kielland K; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus JV, 2019, 'The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination', Clinical Infectious Diseases, 69, pp. 2218 - 2227, http://dx.doi.org/10.1093/cid/ciz714

Lafferty L; Rance J; Treloar C, 2019, '‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures', Drugs: Education, Prevention and Policy, 26, pp. 502 - 507, http://dx.doi.org/10.1080/09687637.2018.1494135

Read P; Gilliver R; Kearley J; Lothian R; Cunningham EB; Chronister KJ; Dore GJ, 2019, 'Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection', Journal of Viral Hepatitis, 26, pp. 1301 - 1310, http://dx.doi.org/10.1111/jvh.13175

Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002

Dillon JF; Miller MH; Robinson EM; Hapca A; Rezaeihemami M; Weatherburn C; McIntyre PG; Bartlett B; Donnan PT; Boyd KA; Dow E, 2019, 'Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care', Journal of Hepatology, 71, pp. 699 - 706, http://dx.doi.org/10.1016/j.jhep.2019.05.033

Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014

Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112

Abayasingam A; Leung P; Eltahla A; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd A; Rodrigo C, 2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection, Genetics and Evolution, 71, pp. 36 - 41, http://dx.doi.org/10.1016/j.meegid.2019.02.032

Dore GJ, 2019, 'HCV reinfection as a positive indication of high-risk population treatment access', Journal of Viral Hepatitis, 26, pp. 516 - 518, http://dx.doi.org/10.1111/jvh.13092

Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016

Rodrigo C; Leung P; Lloyd AR; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Eltahla AA, 2019, 'Genomic variability of within-host hepatitis C variants in acute infection', Journal of Viral Hepatitis, 26, pp. 476 - 484, http://dx.doi.org/10.1111/jvh.13051

Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ, 2019, 'Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy', International Journal of Drug Policy, 66, pp. 73 - 79, http://dx.doi.org/10.1016/j.drugpo.2019.01.011

Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3

Dore G; Feld J; Thompson A; Martinello M; Muir A; Agarwal K; Mullhaupt B; Wedemeyer H; Lacombe K; Matthews G; Schultz M; Mercade GE; Kho D; Filep E; Petoumenos K; Marks P; Tatsch F; dos Santos AGP; Gane E, 2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, 70, pp. E110 - E110, http://dx.doi.org/10.1016/S0618-8278(19)30196-3

Safreed-Harmon K; Blach S; Aleman S; Kielland KB; Bollerup S; Cooke G; Dalgard O; Dillon J; Dore G; Du Berg A-S; Grebely J; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus J, 2019, 'The consensus hepatitis C cascade of care: Methodology and initial findings from three countries', JOURNAL OF HEPATOLOGY, 70, pp. E333 - E334, http://dx.doi.org/10.1016/S0618-8278(19)30651-6

Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222

Cooke GS; Andrieux-Meyer I; Applegate TL; Atun R; Burry JR; Cheinquer H; Dusheiko G; Feld JJ; Gore C; Griswold MG; Hamid S; Hellard ME; Hou JL; Howell J; Jia J; Kravchenko N; Lazarus JV; Lemoine M; Lesi OA; Maistat L; McMahon BJ; Razavi H; Roberts TR; Simmons B; Sonderup MW; Spearman CW; Taylor BE; Thomas DL; Waked I; Ward JW; Wiktor SZ; Abdo A; Aggarwal R; Aghemo A; Al-Judaibi B; Al Mahtab M; Altaf A; Ameen Z; Asselah T; Baatarkkhuu O; Barber E; Barnes E; Boulet P; Burrows L; Butsashvili M; Chan E; Chow C; Cowie B; Cunningham C; de Araujo A; Diap G; Dore G; Doyle J; Elsayed M; Fajardo E; Gane E; Getehun A; Goldberg D; Got T; Hickman M; Hill A; Hutchinson S; Jones C; Kamili S; Khan A; Lee A; Lee TY; Malani J; Morris TM; Nayagam S; Njouom R; Ocama P; Pedrana A; Peeling R; Reddy A; Roberts T; Sacks J; Sarin S; Shimakawa Y; Silva M; Skala P; Taylor-Robinson S; Thompson A; Thursz M; Tonganibeia A; Wallace J; Ward J; Wolff F; Vickerman P; Yau J, 2019, 'Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission', The Lancet Gastroenterology and Hepatology, 4, pp. 135 - 184, http://dx.doi.org/10.1016/S2468-1253(18)30270-X

Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L, 2019, 'Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia', Journal of Hepatology, 70, pp. 33 - 39, http://dx.doi.org/10.1016/j.jhep.2018.09.030

Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013

Foster GR; Dore GJ; Wang S; Grebely J; Sherman KE; Baumgarten A; Conway B; Jackson D; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar H; Asatryan A; Hu Y; Mensa FJ, 2019, 'Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies', Drug and Alcohol Dependence, 194, pp. 487 - 494, http://dx.doi.org/10.1016/j.drugalcdep.2018.11.007

Grebely J; Larney S; Peacock A; Colledge S; Leung J; Hickman M; Vickerman P; Blach S; Cunningham EB; Dumchev K; Lynskey M; Stone J; Trickey A; Razavi H; Mattick RP; Farrell M; Dore GJ; Degenhardt L, 2019, 'Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs', Addiction, 114, pp. 150 - 166, http://dx.doi.org/10.1111/add.14393

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5

Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthews G, 2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, 70, pp. e734 - e734, http://dx.doi.org/10.1016/s0618-8278(19)31468-9

Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013

Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004

Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C, 2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, 25, pp. 1526 - 1532, http://dx.doi.org/10.1111/jvh.12987

Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011

Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2

Grebely J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster GR; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Schnell G; Alami NN; Zhang Z; Dumas E; Dore GJ, 2018, 'Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials', Open Forum Infectious Diseases, 5, pp. ofy248, http://dx.doi.org/10.1093/ofid/ofy248

Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J, 2018, 'The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat', Journal of Hepatology, 69, pp. 1188 - 1196, http://dx.doi.org/10.1016/j.jhep.2018.06.016

Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917

Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy033

Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010

Bartlett SR; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Dore GJ; Russell DB, 2018, 'Demonstration of near-elimination of Hepatitis C virus among a prison population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project', Clinical Infectious Diseases, 67, pp. 460 - 463, http://dx.doi.org/10.1093/cid/ciy210

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5

Dore GJ; Hajarizadeh B, 2018, 'Elimination of Hepatitis C Virus in Australia: Laying the Foundation', Infectious Disease Clinics of North America, 32, pp. 269 - 279, http://dx.doi.org/10.1016/j.idc.2018.02.006

Dore G; Hoy J; Phanuphak P; Levy J; Lewin SR, 2018, 'Professor David Cooper OBITUARY', AIDS, 32, pp. 1205 - 1206, http://dx.doi.org/10.1097/QAD.0000000000001840

Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003

Back to profile page